Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (1598)	1/30/2003 9:25:23 AM
From: tuck	Respond to of 1728

This is why the jump: >>SANTA CLARA, Calif., Jan. 30 /PRNewswire-FirstCall/ -- Roche and Affymetrix, Inc. (Nasdaq: AFFX - News) today announced an agreement in which Affymetrix grants Roche access to its patented GeneChip® brand technologies to develop and commercialize diagnostic products in a broad range of human disease areas. With these technologies, Roche Diagnostics will develop and market tests for a wide range of diseases such as cancer, osteoporosis, cardiovascular, metabolic, infectious, and inflammatory diseases. The agreement gives Roche non-exclusive rights to Affymetrix' array and instrument technologies for up to 18 years. It will enable Roche to create and market GeneChip laboratory tests for DNA analysis, genotyping, and resequencing applications, as well as for RNA expression analysis. "Affymetrix' technology is highly complementary to our polymerase chain reaction (PCR) technology," stated Heino von Prondzynski, Head of Roche Diagnostics and a member of Roche's Corporate Executive Committee. "We believe that creating targeted microarray expression profiles for cancer, and genotyping and resequencing profiles for other diseases will enable us to develop and commercialize novel standardized diagnostic solutions, taking this exciting technology out of the research lab and into the clinical setting. This will allow physicians to tailor therapy for individual patients." "Roche and Affymetrix have become partners in creating genetic tests to aid clinicians in the diagnosis and treatment of human disease," added Stephen P.A. Fodor, Ph.D., the Chairman and CEO of Affymetrix. "We believe the synergies between our GeneChip platform and Roche's PCR technology will establish new standards for genetic clinical testing. We are thrilled to be at the forefront of this new marketplace with Roche." Fodor noted that he expects these tests to become as common in patient care as the X-ray, the EKG, and other routine examinations. Together with Affymetrix, Roche will undertake research projects to develop and validate specific tests, along with clinical trials for those tests. The two companies will also collaborate on high-throughput packaging and instrument technologies for genetic tests for bringing state-of-the-art array scanning to diagnostic laboratories. Microarrays enable researchers to qualitatively and quantitatively measure gene expression levels in a broad range of biologically relevant organisms. They are also used for DNA analysis applications including mapping, genotyping, and resequencing. DNA microarrays were the first high-throughput tool for studying gene function. Under the terms of the agreement, Affymetrix will receive a one-time, upfront payment of 70 million US dollars. Affymetrix may also receive other compensation, including royalties on sales of diagnostic kits and milestone payments for technical and commercial achievements. Conference Call for More Information Affymetrix will host a conference call at 5:00 am Pacific Time, Thursday, January 30 to discuss the Affymetrix/Roche deal. The dial-in number for domestic callers will be 888-737-3798, and for international callers 706-643-2578. A replay of the conference call will be available until 8:00 a.m. Pacific Time on February 6. The replay number for domestic callers will be 800-642-1687 and for international callers 706-645-9291, passcode 10054#. A webcast of the conference call and a replay will also be available at www.affymetrix.com. The conference call, replay, and webcast are open to all interested parties.<< snip And an upgrade from SSB. Cheers, Tuck

To: tom pope who wrote (1598)	1/30/2003 10:30:40 AM
From: Jibacoa	Read Replies (1) \| Respond to of 1728

Not too much to complain about AFFX <g> It has been up as much as 16.87% today after the news of its deal with Roche and the stock opened on a good up-gap. It traded at 25.50 at 9.33 AM and it seems it should be able to close above its January 14 H of 25.39. Although up-gaps oftentimes get closed, and the stock still has some hurdles,: (the Dec.12 H of 25.91 the Nov.29 H at 26.13),before it can test its Nov.21 H at 29.17 I think I will add some to my position at today's levels since I continue to like the long term outlook.<g> siliconinvestor.com siliconinvestor.com Bernard